myocardial  xxxd1773xxx  augmentation with high-dose pdeiii inhibitor in terminal warm blood cardioplegia.  phosphodiesterase (pde) iii inhibitors have been reported in various cellular protective activities via the  xxxd1773xxx  (camp) pathway. we investigated the effects of  xxxd2341xxx  on ischemia/reperfusion injury and intracellular calcium (ca2+) handling if utilized as a component of terminal warm blood cardioplegia (twbcp).